{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:35:14Z","timestamp":1789385714231,"version":"build-2803163510"},"reference-count":62,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,4,18]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To understand stakeholders\u2019 perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa, and to identify key bottlenecks to improve the supply of commodities for neglected tropical diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Desk reviews and qualitative in-depth interview study with purposive sampling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A landscape analysis through literature and desk review was performed. Next, 29 representatives from international organisations, non-governmental agencies, national control programmes from six countries (Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda) and manufacturers were interviewed between May and July 2018. Participants were selected purposively and expanded through a snowballing technique.Data analysis was aided by NVivo, applying the framework method as a part of the thematic content analysis approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The barriers along the visceral leishmaniasis (VL) supply chain were identified as emerging themes, grouped across supply chain activities and health systems component(s). Stakeholders expressed the perception of progress, but bottlenecks persist. VL medicines, in general, lack multisource production capacity and with small market volume, expansion of suppliers is difficult. Procurement is plagued by forecasting difficulties, complex regulatory policies and procedures, and distribution challenges. Weak communication and coordination across different levels resulted in shortages and loss of trust among different actors. Cross-cutting issues spanned from limited political and resource commitment due to low awareness and limited in-country capacity. However, study respondents were optimistic to pursue several remedies, most importantly to build bridges between supply and demand sides through continued dialogue and collaborations. Diagnostics supply has mostly been overlooked; thus, improved investment in this area is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addressing supply barriers in eastern Africa requires consistent, specific efforts at the global and national levels, progressing from current partnerships and agreements. Priority actions include pooled procurement, improved forecast, and increased commitment and resources. Sustainability remains an elusive goal, yet to be integrated into discussions moving forward.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-029141","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:45:36Z","timestamp":1559285136000},"page":"e029141","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03129646","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8830","authenticated-orcid":false,"given":"Temmy","family":"Sunyoto","sequence":"first","affiliation":[{"name":"Public Health Department, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Potet","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res Access Campaign, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet","family":"den Boer","sequence":"additional","affiliation":[{"name":"Medical Department, Artsen zonder Grenzen, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[{"name":"Medical Department, Artsen zonder Grenzen, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A R","family":"Postigo","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ravinetto","sequence":"additional","affiliation":[{"name":"Public Health Department, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[{"name":"VL Clinical Program, Drugs for Neglected Disease Initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Picado","sequence":"additional","affiliation":[{"name":"Instituto de Salud Global Barcelona, Barcelona, Spain"},{"name":"Neglected Tropical Diseases Department, FIND, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Boelaert","sequence":"additional","affiliation":[{"name":"Public Health Department, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"2025121514432103000_9.5.e029141.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09096-7"},{"key":"2025121514432103000_9.5.e029141.2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"2025121514432103000_9.5.e029141.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.4.361"},{"key":"2025121514432103000_9.5.e029141.4","first-page":"521","article-title":"Global leishmaniasis surveillance update, 1998-2016","volume":"40","author":"World Health Organisation","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2025121514432103000_9.5.e029141.5","first-page":"287","article-title":"Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014","volume":"91","author":"WHO","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2025121514432103000_9.5.e029141.6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13071-016-1743-7","article-title":"A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries","volume":"9","author":"Al-Salem","year":"2016","journal-title":"Parasit Vectors"},{"key":"2025121514432103000_9.5.e029141.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002720"},{"key":"2025121514432103000_9.5.e029141.8","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.4.862"},{"key":"2025121514432103000_9.5.e029141.9","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.12-0585"},{"key":"2025121514432103000_9.5.e029141.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2009.02279.x"},{"key":"2025121514432103000_9.5.e029141.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000355"},{"key":"2025121514432103000_9.5.e029141.12","doi-asserted-by":"crossref","first-page":"e00048","DOI":"10.1128\/CMR.00048-18","article-title":"Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2025121514432103000_9.5.e029141.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70011-6"},{"key":"2025121514432103000_9.5.e029141.14","unstructured":"World Health Organization. Control of the leishmaniases: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases,Geneva, 22\u201326 March 2010. Geneva: World Health Organ Tech Rep Ser, 2010:186."},{"key":"2025121514432103000_9.5.e029141.15","doi-asserted-by":"crossref","unstructured":"Musa A , Khalil E , Hailu A , et al . Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis 2012;6.doi:10.1371\/journal.pntd.0001674","DOI":"10.1371\/journal.pntd.0001674"},{"key":"2025121514432103000_9.5.e029141.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-7-199604010-00007"},{"key":"2025121514432103000_9.5.e029141.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01298-10"},{"key":"2025121514432103000_9.5.e029141.18","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12238"},{"key":"2025121514432103000_9.5.e029141.19","doi-asserted-by":"publisher","DOI":"10.1086\/587899"},{"key":"2025121514432103000_9.5.e029141.20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002613"},{"key":"2025121514432103000_9.5.e029141.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004412"},{"key":"2025121514432103000_9.5.e029141.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis716"},{"key":"2025121514432103000_9.5.e029141.23","first-page":"2","article-title":"Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (Review) Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease","volume":"6","author":"Boelaert","year":"2014","journal-title":"Cochran Libr"},{"key":"2025121514432103000_9.5.e029141.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03635.x"},{"key":"2025121514432103000_9.5.e029141.25","unstructured":"KalaCORE. Visceral leishmaniasis treatment access - the reality on the ground in Sudan. WorldLeish6, 2017."},{"key":"2025121514432103000_9.5.e029141.26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4269\/ajtmh.17-0872","article-title":"\u201ckala-Azar is a Dishonest Disease\u201d: Community perspectives on access barriers to visceral leishmaniasis (Kala-Azar) diagnosis and care in Southern Gadarif, Sudan","volume":"98","author":"Sunyoto","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2025121514432103000_9.5.e029141.27","doi-asserted-by":"crossref","first-page":"e0006778","DOI":"10.1371\/journal.pntd.0006778","article-title":"Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study","volume":"12","author":"Coulborn","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2025121514432103000_9.5.e029141.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002456"},{"key":"2025121514432103000_9.5.e029141.29","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-1"},{"key":"2025121514432103000_9.5.e029141.30","doi-asserted-by":"publisher","DOI":"10.1186\/1478-4491-6-1"},{"key":"2025121514432103000_9.5.e029141.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004042"},{"key":"2025121514432103000_9.5.e029141.32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(18)30351-7","article-title":"Sustainable access to deworming drugs in a changing landscape","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025121514432103000_9.5.e029141.33","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.4.962"},{"key":"2025121514432103000_9.5.e029141.34","doi-asserted-by":"crossref","unstructured":"Reich MR , Frost LJ . Research Studies for Promoting Access to Health Technologies in Poor Countries. Access 2010(June):28\u201330.","DOI":"10.1377\/hlthaff.28.4.962"},{"key":"2025121514432103000_9.5.e029141.35","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czs108"},{"key":"2025121514432103000_9.5.e029141.36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4161\/23288604.2014.968005","article-title":"Health Product Supply Chains in Developing Countries: Diagnosis of the Root Causes of Underperformance and an Agenda for Reform","volume":"1","author":"Yadav","year":"2015","journal-title":"Heal Syst Reform"},{"key":"2025121514432103000_9.5.e029141.37","unstructured":"Ritchie J , Lewis J . Qualitative research practice: a guide for social science students and researchers. London: Sage, 2003."},{"key":"2025121514432103000_9.5.e029141.38","first-page":"117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol","volume":"13","author":"Gale","year":"2013","journal-title":"BioMed Central"},{"key":"2025121514432103000_9.5.e029141.39","first-page":"26152","article-title":"What can \u201cthematic analysis\u201d offer health and wellbeing researchers? Int J Qual Stud Health Well-being","volume":"9","author":"Braun","year":"2014","journal-title":"Taylor & Francis"},{"key":"2025121514432103000_9.5.e029141.40","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121514432103000_9.5.e029141.41","doi-asserted-by":"publisher","DOI":"10.3109\/03639041003796648"},{"key":"2025121514432103000_9.5.e029141.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000709"},{"key":"2025121514432103000_9.5.e029141.43","first-page":"785","article-title":"Registering New Drugs : The African Context","volume":"100","author":"Wellcome B","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025121514432103000_9.5.e029141.44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pmed.1000411","article-title":"Registering new drugs for low-income countries: the African challenge","volume":"8","author":"Moran","year":"2011","journal-title":"PLoS Med"},{"key":"2025121514432103000_9.5.e029141.45","unstructured":"World Health Organization. WHO bi-regional consultation on the status of implementation of leishmaniasis control strategies and epidemiological situations in Eastern Africa. Addis Ababa, 2018."},{"key":"2025121514432103000_9.5.e029141.46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5639\/gabij.2013.0202.022","article-title":"Access to liposomal generic formulations: beyond AmBisome and Doxil\/Caelyx","volume":"2","author":"Gaspani","year":"2013","journal-title":"Generics Biosimilars Initiat J"},{"key":"2025121514432103000_9.5.e029141.47","unstructured":"WHO. WHO and Gilead sign agreement for enhanced access to visceral leishmaniasis treatment [Internet]. 2011 http:\/\/www.who.int\/neglected_diseases\/Gilead_donation_2011\/en\/ (cited 2018 Sep 17)."},{"key":"2025121514432103000_9.5.e029141.48","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00801.x"},{"key":"2025121514432103000_9.5.e029141.49","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-7-39"},{"key":"2025121514432103000_9.5.e029141.50","doi-asserted-by":"crossref","unstructured":"Moon S , Bermudez J , \u2019t Hoen E . Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? PLoS Med 2012;9.doi:10.1371\/journal.pmed.1001218","DOI":"10.1371\/journal.pmed.1001218"},{"key":"2025121514432103000_9.5.e029141.51","doi-asserted-by":"crossref","unstructured":"Boelaert M , Verdonck K , Menten J , et al . Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane database Syst Rev 2014;6.","DOI":"10.1002\/14651858.CD009135.pub2"},{"key":"2025121514432103000_9.5.e029141.52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38917.503056.7C"},{"key":"2025121514432103000_9.5.e029141.53","doi-asserted-by":"crossref","unstructured":"van Griensven J , Diro E , Lopez-Velez R , et al . A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward? PLoS Negl Trop Dis 2014;8.doi:10.1371\/journal.pntd.0003011","DOI":"10.1371\/journal.pntd.0003011"},{"key":"2025121514432103000_9.5.e029141.54","doi-asserted-by":"crossref","unstructured":"Sunyoto T , Adam GK , Atia AM , et al . \"Kala-Azar is a Dishonest Disease\": Community Perspectives on Access Barriers to Visceral Leishmaniasis (Kala-Azar) Diagnosis and Care in Southern Gadarif, Sudan. Am J Trop Med Hyg 2018;98.doi:10.4269\/ajtmh.17-0872","DOI":"10.4269\/ajtmh.17-0872"},{"key":"2025121514432103000_9.5.e029141.55","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0140-6736(18)33116-7","article-title":"Boosting quality diagnostics could give Africa better health","volume":"392","author":"Makoni","year":"2018","journal-title":"Lancet"},{"key":"2025121514432103000_9.5.e029141.56","unstructured":"WHO. WHO | WHO aims to improve access to antileishmanial medicines in affected countries: WHO. World Health Organization, 2016."},{"key":"2025121514432103000_9.5.e029141.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2012.05.044"},{"key":"2025121514432103000_9.5.e029141.58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000243"},{"key":"2025121514432103000_9.5.e029141.59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hpm.822","article-title":"Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program","volume":"21","author":"DeRoeck","year":"2006","journal-title":"Int J Health Plann Manage"},{"key":"2025121514432103000_9.5.e029141.60","unstructured":"Management Sciences for Health. Toward Building Resilient Pharmaceutical Systems: SIAPS Final Report. Arlington, 2017."},{"key":"2025121514432103000_9.5.e029141.61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(16)31599-9","article-title":"Essential medicines for universal health coverage","volume":"389","author":"Wirtz","year":"2017","journal-title":"Lancet"},{"key":"2025121514432103000_9.5.e029141.62","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trv060"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-029141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:43:30Z","timestamp":1765838610000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-029141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,30]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjopen-2019-029141"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-029141","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}